Shield Therapeutics plc
("Shield" or the "Group" or the "Company")
Director/PDMR shareholding
London, UK, 21 January 2021: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), announces that Hans Peter Hasler, Non-Executive Chairman, has acquired 100,000 Ordinary Shares in the Company on 20 January 2021 for consideration of £0.59 per Ordinary Share. Following the transaction, Mr Hasler holds 100,000 shares.
The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1 | Details of the person discharging managerial responsibilities/person closely associated
| |
| a) | Name
| Hans Peter Hasler
|
| 2 | Reason for the notification
| |
| a) | Position/status
| Chairman |
| b) | Initial notification/ Amendment
| Initial Notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |
| a) | Name
| Shield Therapeutics plc |
| b) | LEI
| 213800G74QWY15FC3W71 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |
| a)
| Description of the financial instrument, type of instrument
Identification code
| Ordinary shares of 1.5p each in the capital of the Company
ISIN of Ordinary Shares: GB00BYV81293 |
| b)
| Nature of the transaction
| Acquisition of Ordinary Shares |
| c) | Price(s) and volume(s)
| £0.59 per Ordinary Share Volumes: 100,000 |
| d) | Aggregated information
-Aggregated volume
-Price
|
100,000
£59,000 |
| e) | Date of the transaction
| 20 January 2021
|
| f) | Place of the transaction
| London Stock Exchange, AIM Market |
For further information please contact:
| Shield Therapeutics plc | |
| Tim Watts, CEO | +44 (0)20 7186 8500 |
|
|
|
| Nominated Adviser and Joint Broker |
|
| Peel Hunt LLP |
|
| James Steel/Dr Christopher Golden | +44 (0)20 7418 8900 |
|
Joint Broker finnCap Ltd Geoff Nash/Matt Radley/Alice Lane |
+44 (0)20 7220 0500 |
|
|
|
| Financial PR & IR Advisor |
|
| Walbrook PR | +44 (0)20 7933 8780 or shield@walbrookpr.com |
| Paul McManus/Lianne Cawthorne | +44 (0)7980 541 893 / +44 (0)7584 391 303 |
About Shield Therapeutics plc
Shield is a de-risked, specialty pharmaceutical company focused on commercialising its lead product, Feraccru®/Accrufer®, a novel, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Feraccru®/Accrufer® has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. Feraccru® is commercialised in the UK and European Union by Norgine B.V. and the Company is currently in the process of evaluating commercialisation options for the US market, including the potential launch of Accrufer® in the US by Shield. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan.
For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
